Recent developments highlight clinical trial progress, intellectual property expansion, funding activities, and AI-driven data initiatives.

• Creative Medical reported a 93% response rate in its Ultrasome knee osteoarthritis pilot study, indicating promising clinical results [N1].
• The company expanded its Ultrasome intellectual property portfolio in September 2026, strengthening its technology base [N2].
• Creative Medical completed enrollment for the ADAPT trial and advanced its Olastrocel product in August 2026 [N3].
• The stock price surged following patent news in August 2026, reflecting market interest in the company's intellectual property [N4].
• The company secured $4.5 million through warrant exercises in July 2026, enhancing its liquidity position [N5].
• Creative Medical advanced Project PHOENIX, a nationwide AI-driven data collection initiative, in June 2026 to support clinical research [N6].
• The ADAPT trial showed functional and pain improvements in chronic lower back pain patients, with positive interim data reported in January 2026 [N7][N8].

Creative Medical has demonstrated clinical progress with positive interim data from the ADAPT trial showing functional and pain improvements in chronic lower back pain patients. The company reported a high response rate in a pilot study for Ultrasome knee osteoarthritis treatment and has expanded its intellectual property portfolio. Its ability to secure funding through warrant exercises and advance AI-driven data initiatives supports ongoing development efforts.

The company has reported no revenue and continues to incur net losses, reflecting the early-stage nature of its clinical programs and reliance on external financing. Clinical trial outcomes remain subject to regulatory and scientific risks. The biotechnology sector's competitive landscape and the need for successful commercialization pose challenges. Financial liquidity, while currently strong, requires careful management to sustain operations through clinical milestones.

Creative Medical's moat is based on its proprietary stem cell therapies, including CELZ-201 (Olastrocel), and its expanding intellectual property portfolio around Ultrasome technology. The company has FDA clearance for clinical trials and is building clinical evidence through the ADAPT trial and other studies. Its collaborations on AI-driven data collection and a specialized management team with biotechnology and financial expertise contribute to its competitive positioning.

• Clinical Trial Risk: The success of the company's products depends on positive clinical trial outcomes and regulatory approvals, which are inherently uncertain.
• Financial Risk: The company has reported net losses and no revenue, relying on financing activities such as warrant exercises to fund operations.
• Regulatory Risk: FDA clearance and ongoing compliance are critical for clinical trials and product development, with potential delays or denials impacting progress.
• Market and Competitive Risk: The biotechnology and medical technology sectors are highly competitive, with rapid innovation and alternative therapies posing challenges.

• Creative Medical Technology Holdings, Inc. is a publicly traded company on NASDAQ under the ticker CELZ [S1].
• The company is incorporated in Nevada and headquartered in Phoenix, AZ [S1].
• As of September 30, 2026, the company had 7,597,557 shares outstanding [S2].
• The company operates in the biotechnology sector focusing on medical technology and stem cell therapies [N1][N3].
• Creative Medical is conducting clinical trials including the FDA-cleared ADAPT trial for chronic lower back pain using its CELZ-201 (Olastrocel) product [N3][N7][N8].
• The ADAPT trial has shown functional and pain improvements in patients with chronic lower back pain [N7][N8].
• The company completed enrollment for the ADAPT trial as of August 2026 [N3].
• Creative Medical reported a 93% response rate in a pilot study for Ultrasome treatment of knee osteoarthritis [N1].
• The company has expanded its Ultrasome intellectual property portfolio as of September 2026 [N2].
• Creative Medical has advanced Project PHOENIX, a nationwide AI-driven data collection initiative [N6].
• The company secured $4.5 million through warrant exercises in July 2026 [N5].
• Financial figures as of September 30, 2026, include cash and equivalents of approximately $4.5 million, current assets of about $6.9 million, and current liabilities of approximately $293,000, resulting in a strong current ratio of 23.66 and cash ratio of 15.37 [S2].
• The company reported zero revenue for the nine months ended September 30, 2026, and a net loss of approximately $2.67 million for the three months ended September 30, 2026 [S2].
• Net loss per share diluted was $0.40 as of September 30, 2026 [S2].
• The company has a history of operating losses and invests heavily in research and development and selling, general and administrative expenses [S2].
• The executive management team includes Timothy Warbington as CEO and Donald Dickerson as CFO, both with extensive experience in biotechnology and finance [S1].
• The company has a board of directors with financial and legal expertise, including an audit committee chaired by Susan Snow [S1].
• Creative Medical has ongoing clinical development programs and intellectual property related to stem cell therapies and medical devices [N2][N3].